Research and development:
The research and development teams in Suzhou, Shanghai and the United States work closely to form a globally integrated R&D platform and carry out the development of the company's rich product pipeline effectively. Our R&D teams consist of leading scientists and researchers with experience in both US biotechnology companies and international pharmaceutical companies. They have gained profound experience in the field of drug development from research institutions, universities and pharmaceutical companies. Most of them have master's or doctoral degrees.
The Group has built a modern pharmaceutical manufacture base in Suzhou Industrial Park, which is designed in strict compliance with the international GMP standard and it is located on total area of about 20,000 ㎡. The construction has been completed and the base will be ready for manufacturing in 2020. The manufacturing base fully applies new international technology. The first production line can reach the production capacity of 4 million tablets per year which will meet the commercial production needs of the company's initial product launch.
The Group will build an efficient, innovative and independent global business operation team for the innovative drugs. In compliance with scientific and professional marketing rules, the company will actively promote products and business operations in China and the international market. At the same time, we would like to explore more business development and cooperation opportunities with global pharmaceutical companies and partners in related fields.